Aduhelm is an amyloid beta-directed antibody used for the treatment of Alzheimer’s disease (AD). 

Recommended Dosage: After an initial titration, the recommended dosage of aduhelm injection is 10 mg/kg. It is administered as an intravenous (IV) infusion over approximately 60 minutes every four weeks and at least 21 days apart. 

In case an infusion is missed, resume administration at the same dose as quickly as possible. Infusions are to be administered every four weeks and at least 21 days apart. 

• Aduhelm 170 mg therapy may cause amyloid related imaging abnormalities-edema (ARIA-E), which can be observed on MRI as brain edema or sulcal effusions, and amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H), which includes microhemorrhage and superficial siderosis.
• Obtain recent (within 12 months) brain MRI prior to starting treatment. The safety of this medicine in patients with any pre-treatment localized superficial siderosis, 10 or more brain microhemorrhages, or with a brain hemorrhage more than 1 cm within 12 months of therapy initiation has not been established.
• Brain MRIs need to be obtained before the 7th infusion (1’st dose of 10 mg/kg) and 12th infusion (6’th dose of 10 mg/kg) of aduhelm 300 mg to evaluate for the existence of asymptomatic ARIA. For patients with radiographic findings of ARIA, enhanced clinical vigilance is needed.
• Urticaria and angioedema were reported in 1 patient in the placebo-controlled time-span of Studies 1 & 2, and emerged during the infusion. Quickly discontinue the infusion upon the 1’st observation of any signs/symptoms consistent with a hypersensitivity reaction, and start apt therapy.

What documents are required to import ADUHELM to India?

ADUHELM (aducanumab-avwa) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is ADUHELM available in India?

ADUHELM (aducanumab-avwa injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

ADUHELM can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of ADUHELM (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for aduhelm price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the ADUHELM (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.